Q2 Earnings Estimate for BSX Issued By Leerink Partnrs

Boston Scientific Corporation (NYSE:BSX) – Investment analysts at Leerink Partnrs issued their Q2 2025 earnings estimates for Boston Scientific in a report released on Monday, June 16th. Leerink Partnrs analyst M. Kratky expects that the medical equipment provider will post earnings per share of $0.73 for the quarter. Leerink Partnrs currently has a “Strong-Buy” rating on the stock. The consensus estimate for Boston Scientific’s current full-year earnings is $2.85 per share. Leerink Partnrs also issued estimates for Boston Scientific’s Q3 2025 earnings at $0.72 EPS, Q4 2025 earnings at $0.73 EPS, Q1 2026 earnings at $0.79 EPS, Q2 2026 earnings at $0.82 EPS, Q3 2026 earnings at $0.84 EPS, Q4 2026 earnings at $0.90 EPS, FY2026 earnings at $3.36 EPS and FY2027 earnings at $3.88 EPS.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings results on Wednesday, April 23rd. The medical equipment provider reported $0.75 EPS for the quarter, topping the consensus estimate of $0.67 by $0.08. The business had revenue of $4.66 billion during the quarter, compared to analysts’ expectations of $4.57 billion. Boston Scientific had a net margin of 11.58% and a return on equity of 18.67%. The firm’s quarterly revenue was up 20.9% compared to the same quarter last year. During the same period last year, the company posted $0.56 earnings per share.

BSX has been the subject of several other reports. Erste Group Bank upgraded shares of Boston Scientific to a “strong-buy” rating in a report on Thursday, May 8th. Royal Bank Of Canada raised their price target on shares of Boston Scientific from $116.00 to $120.00 and gave the stock an “outperform” rating in a report on Thursday, April 24th. Needham & Company LLC restated a “buy” rating and set a $115.00 price target on shares of Boston Scientific in a report on Wednesday, May 28th. BTIG Research reaffirmed a “buy” rating and set a $124.00 price objective on shares of Boston Scientific in a research report on Wednesday, April 23rd. Finally, Truist Financial raised their price objective on shares of Boston Scientific from $113.00 to $117.00 and gave the company a “buy” rating in a research report on Thursday, April 24th. Twenty-two research analysts have rated the stock with a buy rating and three have given a strong buy rating to the company. Based on data from MarketBeat, Boston Scientific has an average rating of “Buy” and a consensus target price of $116.09.

Boston Scientific Stock Performance

BSX stock opened at $101.72 on Tuesday. The company has a debt-to-equity ratio of 0.47, a quick ratio of 0.88 and a current ratio of 1.45. The stock has a market cap of $150.49 billion, a P/E ratio of 74.25, a P/E/G ratio of 2.62 and a beta of 0.68. The firm has a 50 day simple moving average of $101.35 and a 200 day simple moving average of $98.89. Boston Scientific has a 52 week low of $71.88 and a 52 week high of $107.17.

Insider Transactions at Boston Scientific

In related news, EVP John Bradley Sorenson sold 4,572 shares of the company’s stock in a transaction on Monday, May 5th. The shares were sold at an average price of $104.54, for a total transaction of $477,956.88. Following the completion of the transaction, the executive vice president now directly owns 18,705 shares in the company, valued at $1,955,420.70. This represents a 19.64% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Michael F. Mahoney sold 164,443 shares of the company’s stock in a transaction on Thursday, May 1st. The shares were sold at an average price of $102.48, for a total transaction of $16,852,118.64. Following the transaction, the chief executive officer now owns 1,535,706 shares of the company’s stock, valued at approximately $157,379,150.88. The trade was a 9.67% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 411,970 shares of company stock worth $42,406,693. 0.50% of the stock is owned by insiders.

Hedge Funds Weigh In On Boston Scientific

Several large investors have recently bought and sold shares of the stock. 1248 Management LLC acquired a new position in Boston Scientific during the 1st quarter valued at $35,000. Modern Wealth Management LLC raised its stake in Boston Scientific by 7.9% during the 1st quarter. Modern Wealth Management LLC now owns 2,974 shares of the medical equipment provider’s stock valued at $300,000 after purchasing an additional 218 shares during the last quarter. Birmingham Capital Management Co. Inc. AL acquired a new position in Boston Scientific during the 1st quarter valued at $202,000. Strs Ohio acquired a new position in Boston Scientific during the 1st quarter valued at $110,830,000. Finally, Advisors Capital Management LLC raised its stake in Boston Scientific by 27.5% during the 1st quarter. Advisors Capital Management LLC now owns 4,400 shares of the medical equipment provider’s stock valued at $444,000 after purchasing an additional 948 shares during the last quarter. 89.07% of the stock is currently owned by institutional investors and hedge funds.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.